You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Research & Development
Imfinzi Approved in the US for Extensive-Stage Small Cell Lung Cancer
31 March 2020 - - Only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit in combination with
Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide), British-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) said.
The approval by the US Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing Imfinzi in combination with SoC platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival versus SoC alone.
SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.
The Phase III CASPIAN trial had two primary endpoints comparing experimental arms to SoC.
In the Imfinzi plus SoC arm, the risk of death was reduced by 27% (equal to a hazard ratio of 0.73; 95% CI 0.59-0.91; p=0.0047), with median OS of 13.0 months versus 10.3 months for SoC alone.
Results also showed an increased confirmed objective response rate in the IMFINZI plus SoC arm (68% versus 58% for SoC alone).
The safety and tolerability for Imfinzi plus SoC was consistent with the known safety profiles of these medicines. The Imfinzi plus SoC data from the CASPIAN trial were published in The Lancet.
The second experimental arm testing tremelimumab added to Imfinzi and SoC recently read out but did not meet the primary endpoint.
Details will be presented at a forthcoming medical meeting.
The most common adverse reactions (≥20% of patients with extensive-stage SCLC) were nausea, fatigue/asthenia and alopecia.
The CASPIAN trial used a fixed dose of Imfinzi (1500 mg) administered every three weeks for four cycles while in combination with chemotherapy and then every four weeks until disease progression as a single medicine.
As part of a broad development programme, Imfinzi is also being tested following concurrent chemoradiation therapy in patients with limited-stage SCLC in the Phase III ADRIATIC trial with data anticipated in 2021.
Imfinzi received its first approval based on the Phase III CASPIAN trial in Singapore for patients with ES-SCLC in February 2020.
Imfinzi in combination with etoposide and either carboplatin or cisplatin is currently under regulatory review for the treatment of ES-SCLC in the 1st-line setting based on the Phase III CASPIAN trial in the EU and Japan.
There are no contraindications for Imfinzi (durvalumab).
Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide), British-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) said.
The approval by the US Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing Imfinzi in combination with SoC platinum-etoposide demonstrated a statistically significant and clinically meaningful improvement in overall survival versus SoC alone.
SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly despite initial response to chemotherapy.
The Phase III CASPIAN trial had two primary endpoints comparing experimental arms to SoC.
In the Imfinzi plus SoC arm, the risk of death was reduced by 27% (equal to a hazard ratio of 0.73; 95% CI 0.59-0.91; p=0.0047), with median OS of 13.0 months versus 10.3 months for SoC alone.
Results also showed an increased confirmed objective response rate in the IMFINZI plus SoC arm (68% versus 58% for SoC alone).
The safety and tolerability for Imfinzi plus SoC was consistent with the known safety profiles of these medicines. The Imfinzi plus SoC data from the CASPIAN trial were published in The Lancet.
The second experimental arm testing tremelimumab added to Imfinzi and SoC recently read out but did not meet the primary endpoint.
Details will be presented at a forthcoming medical meeting.
The most common adverse reactions (≥20% of patients with extensive-stage SCLC) were nausea, fatigue/asthenia and alopecia.
The CASPIAN trial used a fixed dose of Imfinzi (1500 mg) administered every three weeks for four cycles while in combination with chemotherapy and then every four weeks until disease progression as a single medicine.
As part of a broad development programme, Imfinzi is also being tested following concurrent chemoradiation therapy in patients with limited-stage SCLC in the Phase III ADRIATIC trial with data anticipated in 2021.
Imfinzi received its first approval based on the Phase III CASPIAN trial in Singapore for patients with ES-SCLC in February 2020.
Imfinzi in combination with etoposide and either carboplatin or cisplatin is currently under regulatory review for the treatment of ES-SCLC in the 1st-line setting based on the Phase III CASPIAN trial in the EU and Japan.
There are no contraindications for Imfinzi (durvalumab).
Login
Related Headlines
US FDA approves Lupin's Meloxicam Capsules
Eisai launches new insomnia drug Dayvigo (Lemborexant) CIV in US
Roche's Tecentriq in combination with Avastin gains FDA approval for most common liver cancer